AN2 Therapeutics, Inc.
NASDAQ:ANTXBiotechnology
Healthcare
$5.22 +0.82%
+$0.04 today
- Market cap
- $198.07M
- Beta
- -0.98
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$1.01
52W Low $1.00High $6.91
Volume 0.79M
Average 0.29M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$38.11M
FY 2025 · Annual
Net Income
-$35.17M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 77K | 0 | 0 | 0 |
| Gross Profit | 0 | (77K) | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 16.91M | 29.51M | 54.87M | 40.49M | 24.77M |
| Selling, General & Admin | 4.67M | 12.75M | 14.76M | 14.07M | 13.34M |
| Operating Expenses | 21.57M | 42.19M | 69.64M | 54.55M | 38.11M |
| Depreciation & Amortization | 0 | 77K | 69.64M | 54.55M | 0 |
| EBITDA | (21.54M) | (40.88M) | 4.9M | 3.23M | (35.17M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (21.57M) | (42.26M) | (69.64M) | (54.55M) | (38.11M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 69K | 1.35M | 4.86M | 5.47M | 2.93M |
| Interest Expense | 0 | 514K | 0 | 0 | 0 |
| Other Income / Expenses | 31K | 1.31M | 4.9M | 3.23M | 2.94M |
| Income Before Tax | (21.54M) | (40.96M) | (64.73M) | (51.32M) | (35.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (21.54M) | (40.96M) | (64.73M) | (51.32M) | (35.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.50) | (2.79) | (2.74) | (1.72) | (1.16) |
| EPS (Diluted) | (1.50) | (2.79) | (2.74) | (1.72) | (1.16) |
| 18.74M | 15.34M | 23.6M | 29.83M | 30.22M | |
| 18.74M | 15.34M | 23.6M | 29.83M | 30.22M |
ANTX Earnings Waterfall · TTM
NASDAQ:ANTX · Revenue to Net Income
Key Ratios
EPS$-1.10
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.5
P/S Ratio0.0
Analysis
$0 of revenue converted into -$34.6M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.10, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 6, 2026 |
How much revenue does ANTX generate?
AN2 Therapeutics, Inc. (ANTX) reported $0.00 of revenue in fiscal 2025.
Is ANTX profitable?
AN2 Therapeutics, Inc. (ANTX) reported -$35.17M of net income.
Continue the stock analysis
Jump to another research area for this company.